Pages that link to "Q71670392"
Jump to navigation
Jump to search
The following pages link to Antagonism of estrogen action with a new benzothiophene derived antiestrogen (Q71670392):
Displaying 50 items.
- Breast cancer prevention (Q24797803) (← links)
- The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice (Q26830744) (← links)
- Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells (Q28343990) (← links)
- Selective estrogen receptor modulators: Women's panacea for the next millennium? (Q33540949) (← links)
- Current and potential future drug treatments for osteoporosis (Q33579316) (← links)
- Estrogen receptor as a target for the prevention of breast cancer (Q33611600) (← links)
- Raloxifene, a new selective estrogen receptor modulator (Q33703846) (← links)
- Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats (Q34118797) (← links)
- Progress in the prevention of breast cancer: concept to reality (Q34132645) (← links)
- The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators (Q34315816) (← links)
- Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance. (Q34502268) (← links)
- Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale (Q35023715) (← links)
- Beyond raloxifene for the prevention of osteoporosis and breast cancer (Q36052490) (← links)
- BF3·Et2O Catalysed 4-Aryl-3-phenyl-benzopyrones, Pro-SERMs, and Their Characterization (Q36059489) (← links)
- The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities (Q36464743) (← links)
- Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer (Q36684234) (← links)
- Selective estrogen receptor modulators and phytoestrogens (Q36984515) (← links)
- New antiestrogens in breast cancer: a review (Q37827575) (← links)
- Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells (Q40861108) (← links)
- Is ICI 182,780 an antiprogestin in addition to being an antiestrogen? (Q40874389) (← links)
- Breast cancer therapies in development. A review of their pharmacology and clinical potential. (Q40883320) (← links)
- Molecular mechanisms and future uses of antiestrogens (Q40892619) (← links)
- Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer (Q40952791) (← links)
- Heterogeneity of Binding Sites and Bioeffects of Raloxifene on the Human Leukemic Cell Line FLG 29.1 (Q41076826) (← links)
- A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens (Q41585210) (← links)
- Tamoxifen: From breast cancer therapy to the design of a postmenopausal prevention maintenance therapy (Q41692879) (← links)
- Proliferation and differentiation of prepubertal mouse vaginal epithelial cells in vitro and the specificity of estrogen-induced growth retardation (Q42137161) (← links)
- De novo design, synthesis and evaluation of a non-steroidal diphenylnaphthyl propylene ligand for the estrogen receptor (Q42438081) (← links)
- Estrogen stimulation of creatine kinase B specific activity in 3T3L1 adipocytes after their differentiation in culture: Dependence on estrogen receptor (Q42450126) (← links)
- Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma (Q44461130) (← links)
- Structure-Based drug design: synthesis, crystal structure, biological evaluation and docking studies of mono- and bis-benzo[ b ]oxepines as non-steroidal estrogens (Q44646687) (← links)
- Control of proliferation of MCF-7 breast cancer cells in a commercial preparation of charcoal-stripped adult bovine serum (Q44904491) (← links)
- The selective estrogen receptor modulator, raloxifene: reproductive assessments following preimplantation exposure in mated female rats (Q47969178) (← links)
- The selective estrogen receptor modulator, raloxifene: reproductive assessments following premating exposure in female rats (Q47969192) (← links)
- Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo (Q48839905) (← links)
- Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells (Q50141897) (← links)
- Early breast cancer (Q57142283) (← links)
- Estrogenic activity of phenol red (Q68466532) (← links)
- Effects of anti-estrogens on bone in castrated and intact female rats (Q69465128) (← links)
- Failure of cannabinoid compounds to stimulate estrogen receptors (Q71874562) (← links)
- Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat (Q73179490) (← links)
- Chemoprevention of breast cancer (Q73206608) (← links)
- Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells (Q73503052) (← links)
- Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor (Q73503403) (← links)
- Agonistic Effect of Tamoxifen Is Dependent on Cell Type, ERE-Promoter Context, and Estrogen Receptor Subtype: Functional Difference between Estrogen Receptors α and β (Q73510974) (← links)
- Ipriflavone inhibits bone resorption in intact and ovariectomized rats (Q73603019) (← links)
- The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells (Q74502081) (← links)
- Raloxifene (Q74507745) (← links)
- Targeted Antiestrogens to Prevent Breast Cancer (Q78240907) (← links)
- Chemoprevention of breast cancer with selective oestrogen-receptor modulators (Q79448439) (← links)